These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34536775)

  • 1. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
    Feng L; Xu X; Zhao K
    Leuk Res; 2021 Dec; 111():106708. PubMed ID: 34536775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SENP1 knockdown potentiates the apoptosis, cell cycle arrest, and reduces cisplatin resistance of diffuse large B cell lymphoma cells via inducing ferroptosis.
    Dong J; Zheng X
    Biochem Cell Biol; 2024 Aug; 102(4):319-330. PubMed ID: 38708853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
    Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
    Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
    Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
    Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G protein nucleolar 3 promotes Non-Hodgkin lymphoma progression by activating the Wnt/β-catenin signaling pathway.
    Dai R; Wu M; Zhang Y; Zhu Z; Shi J
    Exp Cell Res; 2021 Dec; 409(2):112911. PubMed ID: 34762898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
    Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
    Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
    Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
    J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway.
    Wang Z; Ran X; Qian S; Hou H; Dong M; Wu S; Ding M; Zhang Y; Zhang X; Zhang M; Chen Q
    Arch Biochem Biophys; 2021 Oct; 710():108998. PubMed ID: 34280359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
    Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
    Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
    Singh RR; Kunkalla K; Qu C; Schlette E; Neelapu SS; Samaniego F; Vega F
    Oncogene; 2011 Dec; 30(49):4874-86. PubMed ID: 21625222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
    Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-κB/STAT3/GPX4 axis.
    Zhong X; Zhang W; Zhang W; Yu N; Li W; Song X
    Cancer Biol Ther; 2024 Dec; 25(1):2403197. PubMed ID: 39345091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
    Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
    Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.